|
US5700909A
(en)
*
|
1993-07-30 |
1997-12-23 |
The Regents Of The University Of California |
Prosaposin and cytokine-derived peptides
|
|
US5571787A
(en)
*
|
1993-07-30 |
1996-11-05 |
Myelos Corporation |
Prosaposin as a neurotrophic factor
|
|
US5861499A
(en)
|
1994-02-10 |
1999-01-19 |
Imclone Systems Incorporated |
Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
|
|
US6448077B1
(en)
|
1994-02-10 |
2002-09-10 |
Imclone Systems, Inc. |
Chimeric and humanized monoclonal antibodies specific to VEGF receptors
|
|
US5840301A
(en)
*
|
1994-02-10 |
1998-11-24 |
Imclone Systems Incorporated |
Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
|
|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
|
US6013256A
(en)
*
|
1996-09-24 |
2000-01-11 |
Protein Design Labs, Inc. |
Method of preventing acute rejection following solid organ transplantation
|
|
GB9825632D0
(en)
*
|
1998-11-23 |
1999-01-13 |
Novartis Ag |
Organic compounds
|
|
FR2793691B1
(fr)
*
|
1999-05-21 |
2003-10-03 |
Hippocampe |
Utilisation d'anticorps reconnaissant le recepteur de l'interleukine-2 dans la prevention et/ou le traitement des infections par les virus du sida
|
|
GB0007911D0
(en)
*
|
2000-03-30 |
2000-05-17 |
Novartis Ag |
Organic compounds
|
|
CA2774959C
(en)
|
2000-08-04 |
2016-05-31 |
Dmi Biosciences, Inc. |
Method of using diketopiperazines and composition containing them
|
|
NZ527302A
(en)
*
|
2001-01-05 |
2006-10-27 |
Abgenix Inc |
Antibodies to insulin-like growth factor I receptor
|
|
AU2002307554A1
(en)
*
|
2001-04-23 |
2002-11-05 |
Abgenix, Inc. |
Anti-alpha3(iv)nc1 monoclonal antibodies and animal model for human anti-glomerular basement membrane autoantibody disease
|
|
NZ530765A
(en)
|
2001-06-26 |
2006-11-30 |
Amgen Fremont Inc |
Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
|
|
EP2298717B1
(de)
|
2001-11-30 |
2015-10-28 |
Biogen MA Inc. |
Antikörper gegen chemotaktische Proteine
|
|
JP2005530490A
(ja)
*
|
2002-03-29 |
2005-10-13 |
シェーリング コーポレイション |
インターロイキン−５に対するヒトモノクローナル抗体および方法およびこれを含む組成物
|
|
AU2003224950B2
(en)
|
2002-04-09 |
2006-09-14 |
Biogen Ma Inc. |
Methods for treating tweak-related conditions
|
|
WO2004002500A1
(en)
*
|
2002-06-28 |
2004-01-08 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
|
|
BR0313331A
(pt)
*
|
2002-08-10 |
2007-07-24 |
Univ Yale |
antagonistas de receptor de nogo
|
|
EP1571970B1
(de)
*
|
2002-10-02 |
2011-08-17 |
DMI Biosciences, Inc. |
Diagnose und überwachung von krankheiten
|
|
EP1460088A1
(de)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
|
|
AU2004231742A1
(en)
*
|
2003-04-16 |
2004-11-04 |
Biogen Idec Ma Inc. |
Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
|
|
US7767641B2
(en)
*
|
2003-04-24 |
2010-08-03 |
Yale University |
Regulator of endothelial cell function and vessel remodeling
|
|
KR20170038128A
(ko)
|
2003-05-15 |
2017-04-05 |
앰피오 파마슈티컬스 인코퍼레이티드 |
Ｔ-세포 매개성 질환의 치료 방법
|
|
OA13358A
(en)
|
2004-01-09 |
2007-04-13 |
Amgen Fremont Inc |
Antibodies to MAdCAM.
|
|
JP4960859B2
(ja)
|
2004-03-12 |
2012-06-27 |
バスジーン セラピューティクス，インコーポレイテッド |
血管形成及び腫瘍成長を阻害するためのポリペプチド化合物
|
|
US7280939B2
(en)
*
|
2004-04-29 |
2007-10-09 |
International Business Machines Corporation |
System and method of analyzing timing effects of spatial distribution in circuits
|
|
NZ552091A
(en)
*
|
2004-07-16 |
2009-09-25 |
Pfizer Prod Inc |
Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
|
|
DE602005026219D1
(de)
*
|
2004-10-01 |
2011-03-17 |
Max Planck Gesellschaft |
Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
|
|
DK1819358T3
(da)
|
2004-11-18 |
2014-10-27 |
Imclone Llc |
Antistoffer mod vaskulær endothel-vækstfaktor-receptor-1
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
JP2008532559A
(ja)
|
2005-03-19 |
2008-08-21 |
メディカル リサーチ カウンシル |
ウイルス感染の治療及び予防又は治療及び予防の改善
|
|
IL296666A
(en)
|
2005-03-23 |
2022-11-01 |
Genmab As |
Antibodies against 38cd for the treatment of multiple myeloma
|
|
US20090053229A1
(en)
*
|
2005-05-12 |
2009-02-26 |
Lee Daniel H S |
Methods of Treating Conditions Involving Neuronal Degeneration
|
|
FR2888850B1
(fr)
|
2005-07-22 |
2013-01-11 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
|
EP2526968A3
(de)
|
2006-01-27 |
2013-05-22 |
Biogen Idec MA Inc. |
Nogo-Rezeptorantagonisten
|
|
JP2007284415A
(ja)
*
|
2006-03-10 |
2007-11-01 |
Daicel Chem Ind Ltd |
アミド又はラクタムの製造法
|
|
JP2009534390A
(ja)
*
|
2006-04-21 |
2009-09-24 |
アムジェン インコーポレイテッド |
生物医薬品製剤のための緩衝剤
|
|
RU2499001C2
(ru)
|
2006-06-30 |
2013-11-20 |
Ново Нордиск А/С |
Антитела к nkg2a и их применения
|
|
AU2007294909A1
(en)
|
2006-09-08 |
2008-03-20 |
Amgen Inc. |
IL-1 family variants
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
NZ576122A
(en)
|
2006-09-26 |
2012-09-28 |
Genmab As |
Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
|
|
FR2906533B1
(fr)
|
2006-09-28 |
2013-02-22 |
Pf Medicament |
Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
|
|
JP5631591B2
(ja)
*
|
2006-10-06 |
2014-11-26 |
アムジエン・インコーポレーテツド |
安定な抗体製剤
|
|
ES2925992T3
(es)
*
|
2006-10-20 |
2022-10-20 |
Amgen Inc |
Formulaciones estables de polipéptidos
|
|
EP2094733A1
(de)
|
2006-11-03 |
2009-09-02 |
U3 Pharma GmbH |
Fgfr4-antikörper
|
|
JP5577098B2
(ja)
*
|
2006-12-21 |
2014-08-20 |
アムジエン・インコーポレーテツド |
ポリペプチドを含有する安定な緩衝化された製剤
|
|
WO2009077483A1
(en)
|
2007-12-14 |
2009-06-25 |
Novo Nordisk A/S |
Antibodies against human nkg2d and uses thereof
|
|
JP5492567B2
(ja)
|
2007-02-02 |
2014-05-14 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
髄鞘形成およびオリゴデンドロサイト分化を促進するためのセマフォリン６ａの使用
|
|
CL2008001887A1
(es)
|
2007-06-29 |
2008-10-03 |
Amgen Inc |
Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
|
|
EP2014681A1
(de)
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Neue Antikörper zur Hemmung der C-Met-Dimerisation und Verwendungen davon
|
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
|
CN101939336B
(zh)
|
2007-11-12 |
2014-05-14 |
U3制药有限公司 |
Axl抗体
|
|
JP5774312B2
(ja)
|
2008-01-24 |
2015-09-09 |
ノボ・ノルデイスク・エー／エス |
ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体
|
|
RU2539110C2
(ru)
*
|
2008-03-13 |
2015-01-10 |
Биотест Аг |
Способ лечения аутоиммунного заболевания (варианты)
|
|
AU2009235622C9
(en)
*
|
2008-03-13 |
2015-07-02 |
Biotest Ag |
Agent for treating disease
|
|
ES2610327T3
(es)
*
|
2008-03-13 |
2017-04-27 |
Biotest Ag |
Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias
|
|
US8217047B2
(en)
*
|
2008-05-27 |
2012-07-10 |
Dmi Acquisition Corp. |
Therapeutic methods and compounds
|
|
CA2730909A1
(en)
*
|
2008-08-28 |
2010-03-04 |
Abbott Biotherapeutics Corp. |
Method for treating multiple sclerosis patients with anti-il2r antibodies
|
|
DK2341937T3
(en)
*
|
2008-09-29 |
2015-02-09 |
Biotest Ag |
Composition for the treatment of a disease
|
|
EP2172485A1
(de)
|
2008-10-01 |
2010-04-07 |
Pierre Fabre Medicament |
Neuartige Anti-CXCR4-Antikörper und ihre Verwendung bei der Krebsbehandlung
|
|
US9469691B2
(en)
|
2008-12-02 |
2016-10-18 |
Pierre Fabre Medicament |
Anti-cMET antibody
|
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
|
AR074439A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Anticuerpo anti-cmet (receptor c-met)
|
|
WO2010107752A2
(en)
|
2009-03-20 |
2010-09-23 |
Amgen Inc. |
Alpha-4-beta-7 heterodimer specific antagonist antibody
|
|
EP2246364A1
(de)
|
2009-04-29 |
2010-11-03 |
Pierre Fabre Médicament |
Antikörper gegen CXCR4 zur Behandlung von HIV
|
|
WO2011000962A2
(en)
|
2009-07-03 |
2011-01-06 |
Bionor Immuno As |
Novel therapeutic and diagnostic means
|
|
JP2013500987A
(ja)
|
2009-07-31 |
2013-01-10 |
アムジェン インコーポレイテッド |
３型メタロプロテイナーゼ組織阻害剤（ｔｉｍｐ−３）に結合するポリペプチド、組成物および方法
|
|
EP2308897A1
(de)
|
2009-10-09 |
2011-04-13 |
Pierre Fabre Medicament |
Chimäre Antikörper spezifisch für CD151 und deren Verwendung zur Behandlung von Krebs
|
|
MX340971B
(es)
|
2009-11-23 |
2016-08-02 |
Amgen Inc * |
Fragmento cristalizable (fc) de anticuerpo monomerico.
|
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
EP2371863A1
(de)
|
2010-03-30 |
2011-10-05 |
Pierre Fabre Médicament |
Menschlische Antikörper gegen CXCR4 zur Behandlung von Krebs
|
|
WO2011130417A2
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
|
|
US9457079B2
(en)
|
2010-05-12 |
2016-10-04 |
The Trustees Of Columbia University In The City Of New York |
Methods for producing enteroendocrine cells that make and secrete insulin
|
|
WO2012012141A1
(en)
|
2010-06-30 |
2012-01-26 |
Amgen Inc. |
Scnn1a/tnfrsf1a fusion proteins in cancer
|
|
SG10201506405YA
(en)
|
2010-08-16 |
2015-10-29 |
Amgen Inc |
Polypeptides That Bind Myostatin, Compositions And Methods
|
|
CA2810844C
(en)
|
2010-09-07 |
2017-03-21 |
Dmi Acquisition Corp. |
Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
|
|
EP2640745B1
(de)
|
2010-09-10 |
2018-11-07 |
MedImmune Limited |
Bivalente und bispezifische antikörper gegen il-6 und il-23
|
|
CA2814908A1
(en)
|
2010-10-27 |
2012-05-03 |
Pierre Fabre Medicament |
Antibodies for the treatment of hiv
|
|
US20140037642A1
(en)
|
2011-02-02 |
2014-02-06 |
Amgen Inc. |
Methods and compositions relating to inhibition of igf-1r
|
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
|
SG10201608087WA
(en)
|
2011-10-10 |
2016-11-29 |
Ampio Pharmaceuticals Inc |
Implantable medical devices with increased immune tolerance, and methods for making and implanting
|
|
EA028343B1
(ru)
|
2011-10-10 |
2017-11-30 |
Ампио Фармасьютикалз, Инк. |
Лечение дегенеративного заболевания сустава
|
|
JP6526414B2
(ja)
|
2011-10-26 |
2019-06-05 |
アムジエン・インコーポレーテツド |
Ｕｖ光曝露から生じるタンパク質の改変と分解を減ずるまたは排除する方法
|
|
CN103841974A
(zh)
|
2011-10-28 |
2014-06-04 |
安皮奥制药股份有限公司 |
鼻炎的治疗
|
|
EP2589609A1
(de)
|
2011-11-03 |
2013-05-08 |
Pierre Fabre Medicament |
Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs
|
|
WO2013092998A1
(en)
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Enzymatic conjugation of antibodies
|
|
CA2868883C
(en)
|
2012-03-30 |
2022-10-04 |
Sorrento Therapeutics Inc. |
Fully human antibodies that bind to vegfr2
|
|
WO2013169734A1
(en)
|
2012-05-07 |
2013-11-14 |
Amgen Inc. |
Anti-erythropoietin antibodies
|
|
DK2854850T3
(da)
|
2012-05-25 |
2021-08-30 |
Sloan Kettering Inst Cancer Res |
Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
|
|
US9175082B2
(en)
|
2012-05-31 |
2015-11-03 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
WO2013182662A1
(en)
|
2012-06-06 |
2013-12-12 |
Bionor Immuno As |
Vaccine
|
|
JP6429771B2
(ja)
|
2012-06-21 |
2018-11-28 |
ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
ｃ−Ｍｅｔに結合する抗原結合タンパク質
|
|
CA2877814A1
(en)
|
2012-06-22 |
2013-12-27 |
Dingqiu HUANG |
Antigen binding proteins that bind ccr2
|
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
EP2872894B1
(de)
|
2012-07-13 |
2019-04-17 |
Innate Pharma |
Screening von konjugierten antikörpern
|
|
WO2014022102A1
(en)
|
2012-08-01 |
2014-02-06 |
Amgen Inc. |
Methods of using anti-apoptotic compounds to modulate one or more properties of a cell culture
|
|
TWI609887B
(zh)
|
2012-11-05 |
2018-01-01 |
皮爾法伯製藥公司 |
新穎的抗原結合蛋白及其作爲治療癌症之定址產物的用途
|
|
WO2014072482A1
(en)
|
2012-11-09 |
2014-05-15 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
WO2014109858A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
|
JP2016508504A
(ja)
|
2013-02-01 |
2016-03-22 |
サンタ マリア バイオセラピューティクス インコーポレイテッド |
対象に対する抗アクチビン−ａ化合物の投与
|
|
FR3004184B1
(fr)
|
2013-02-26 |
2016-03-18 |
Agronomique Inst Nat Rech |
Anticorps anti-gluten desamide et utilisations.
|
|
WO2014159764A1
(en)
|
2013-03-14 |
2014-10-02 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
|
EP2968582B1
(de)
|
2013-03-15 |
2020-07-01 |
Innate Pharma |
Festphasen-tgase-vermittelte konjugation von antikörpern
|
|
MX2015010937A
(es)
|
2013-03-15 |
2015-10-29 |
Ampio Pharmaceuticals Inc |
Composiciones para la movilizacion, autodireccion, expansion y diferenciacion de celulas madre y metodos para usar las mismas.
|
|
EP3010547B1
(de)
|
2013-06-20 |
2021-04-21 |
Innate Pharma |
Enzymatische konjugation von polypeptiden
|
|
EP3010548A1
(de)
|
2013-06-21 |
2016-04-27 |
Innate Pharma |
Enzymatische konjugation von polypeptiden
|
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
|
CA2923145C
(en)
|
2013-09-05 |
2025-09-16 |
Amgen Inc. |
MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
|
|
ES2892923T3
(es)
|
2013-09-05 |
2022-02-07 |
Ab2 Bio Sa |
Proteína de unión a IL-18 (IL-18BP) en enfermedades inflamatorias
|
|
WO2015036956A1
(en)
|
2013-09-12 |
2015-03-19 |
Institut National De La Sante Et De La Recherche Medicale |
Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies
|
|
ES3030960T3
(en)
|
2013-10-31 |
2025-07-02 |
Amgen Inc |
Use of monensin to regulate glycosylation of recombinant proteins
|
|
BR112016017606A2
(pt)
|
2014-01-29 |
2017-10-10 |
Amgen Inc |
superexpressão de reguladores de via de n-glicosilação para modular a glicosilação de proteínas recombinantes
|
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
|
HRP20192254T1
(hr)
|
2014-04-25 |
2020-03-06 |
Pierre Fabre Medicament |
Konjugat antitijela i lijeka i njegova upotreba u liječenju karcinoma
|
|
BR112016024575B1
(pt)
|
2014-04-25 |
2024-02-27 |
Pierre Fabre Medicament |
Anticorpo monoclonal de internalização, ou um fragmento de ligação a igf-1r de internalização do mesmo, seus usos, hibridoma murino, conjugado anticorpo-fármaco, e composição farmacêutica e seus usos
|
|
PT3134124T
(pt)
|
2014-04-25 |
2019-06-03 |
Pf Medicament |
Conjugado anticorpo-fármaco igf-1r e a sua utilização para o tratamento de cancro
|
|
CA2985344A1
(en)
|
2014-06-26 |
2015-12-30 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
|
WO2016028790A1
(en)
|
2014-08-18 |
2016-02-25 |
Ampio Pharmaceuticals, Inc. |
Treatment of joint conditions
|
|
JP2017529331A
(ja)
|
2014-08-22 |
2017-10-05 |
ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
Ｃｘｃｒ３に結合する抗原結合タンパク質
|
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
|
IL312777A
(en)
|
2014-09-28 |
2024-07-01 |
Univ California |
Modulation of stimulatory and non-stimulatory myeloid cells
|
|
EP3207059A1
(de)
|
2014-10-17 |
2017-08-23 |
Amgen Inc. |
Gegen angiopoietin-1 und angiopoietin-2 gerichtete antikörper für augentherapien
|
|
IL292578A
(en)
|
2015-02-13 |
2022-06-01 |
Sorrento Therapeutics Inc |
Antibody therapeutics that bind ctla4
|
|
CA2972689A1
(en)
|
2015-03-05 |
2016-09-09 |
Ab2 Bio Sa |
Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
|
|
WO2016156557A1
(en)
|
2015-04-03 |
2016-10-06 |
Alienor Farma |
Monoclonal antibody to human line-1 orf2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
|
|
ES2927119T3
(es)
|
2015-04-08 |
2022-11-02 |
Sorrento Therapeutics Inc |
Productos terapéuticos de anticuerpos que se unen a CD38
|
|
US20180140694A1
(en)
|
2015-05-04 |
2018-05-24 |
Bionor Immuno As |
Dosage regimen for hiv vaccine
|
|
US11389512B2
(en)
|
2015-06-22 |
2022-07-19 |
Ampio Pharmaceuticals, Inc. |
Use of low molecular weight fractions of human serum albumin in treating diseases
|
|
WO2017058944A1
(en)
|
2015-09-29 |
2017-04-06 |
Amgen Inc. |
Asgr inhibitors
|
|
US10858423B2
(en)
|
2015-10-26 |
2020-12-08 |
Pierre Fabre Medicament |
Composition for the treatment of IGF-1R expressing cancer
|
|
WO2017114976A1
(en)
|
2015-12-31 |
2017-07-06 |
Progastrine Et Cancers S.À R.L. |
Compositions and methods for detecting and treating esophageal cancer
|
|
CN108700588A
(zh)
|
2015-12-31 |
2018-10-23 |
普莱戈斯瑞恩癌症有限责任公司 |
用于检测和治疗胃癌的组合物和方法
|
|
CA3194356C
(en)
|
2015-12-31 |
2025-04-08 |
Progastrine Et Cancers S.A R.L. |
Compositions and methods for detecting and treating ovarian cancer
|
|
BR112018015480A2
(pt)
|
2016-01-29 |
2019-05-21 |
Sorrento Therapeutics, Inc. |
proteínas de ligação ao antígeno que se ligam a pd-l1
|
|
EP3427055A1
(de)
|
2016-03-07 |
2019-01-16 |
Pierre Fabre Medicament |
Neues universelles verfahren zur aufnahme und analyse von adcs zur charakterisierung der wirkstoffverteilung und des wirkstoff-antikörper-verhältnisses bei biologischen proben
|
|
EP3455359B1
(de)
|
2016-05-11 |
2022-03-09 |
Amgen Inc. |
Direkte auswahl von zellen, die hohe konzentrationen von heteromeren proteinen exprimieren, mittels intragener komplementierungsvektoren der glutaminsynthetase
|
|
MX2019000149A
(es)
|
2016-07-07 |
2019-09-23 |
Iovance Biotherapeutics Inc |
Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas.
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
CN110234355B
(zh)
|
2017-02-01 |
2021-11-09 |
浙江时迈药业有限公司 |
单体人IgG1 Fc和双特异性抗体
|
|
US11879014B2
(en)
|
2017-03-17 |
2024-01-23 |
Tusk Therapeutics Ltd. |
Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
|
|
EA201992317A1
(ru)
|
2017-03-30 |
2020-03-05 |
Эсс-Прогастрин Са |
Композиции и способы для диагностики рака легких
|
|
EP3601347B1
(de)
|
2017-03-30 |
2021-11-03 |
Progastrine et Cancers S.à r.l. |
Zusammensetzungen und verfahren zur detektion und behandlung von prostatakrebs mit progastrin bindenden molekül
|
|
EP3652211A1
(de)
|
2017-07-14 |
2020-05-20 |
Pfizer Inc. |
Antikörper gegen madcam
|
|
EP3444272A1
(de)
|
2017-08-17 |
2019-02-20 |
International-Drug-Development-Biotech |
Behandlung von ck8-positivem krebs in verbindung mit dem k-ras-genstatus
|
|
WO2019046600A1
(en)
|
2017-08-30 |
2019-03-07 |
Amgen Inc. |
INSULIN-RELATED GROWTH FACTOR 1 RECEPTOR BINDING PROTEINS (IGF-1R) AND METHODS OF USE
|
|
KR102461238B1
(ko)
|
2017-12-05 |
2022-11-01 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
암을 치료하기 위한 항-프로가스트린 항체와 면역치료 사이의 병용 치료
|
|
WO2019145537A1
(en)
|
2018-01-26 |
2019-08-01 |
Ecs-Progastrin Sa |
Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
|
|
TW202000699A
(zh)
|
2018-02-27 |
2020-01-01 |
瑞士商Ｅｃｓ前胃泌激素公司 |
將前胃泌激素作為生物標記用於免疫療法的技術
|
|
US20210355199A1
(en)
|
2018-06-28 |
2021-11-18 |
University Of Virginia Patent Foundation |
Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
|
|
WO2020065408A1
(en)
|
2018-09-27 |
2020-04-02 |
Pierre Fabre Medicament |
Sulfomaleimide-based linkers and corresponding conjugates
|
|
JP2022502443A
(ja)
|
2018-09-28 |
2022-01-11 |
ピエール、ファーブル、メディカマン |
癌の処置のための新規な免疫サイトカイン
|
|
KR20210087965A
(ko)
|
2018-10-29 |
2021-07-13 |
1글로브 바이오메디칼 씨오., 엘티디. |
신규 합리적으로 디자인된 단백질 조성물
|
|
WO2020215020A1
(en)
|
2019-04-18 |
2020-10-22 |
Qlsf Biotherapeutics Inc. |
Humanized anti-pd-l1 antibodies
|
|
CN113811329B
(zh)
|
2019-04-19 |
2025-10-14 |
天科雅生物科技有限公司 |
抗pd-1抗体和其用途
|
|
EP3962941A4
(de)
|
2019-04-30 |
2023-05-10 |
Gigagen, Inc. |
Rekombinante polyklonale proteine und verfahren zur verwendung davon
|
|
WO2020231629A1
(en)
|
2019-05-16 |
2020-11-19 |
Snake River Bioscience, Inc. |
Compositions and methods for the treatment of major depressive disorder
|
|
MX2021014931A
(es)
|
2019-06-07 |
2022-01-24 |
Amgen Inc |
Construcciones de union biespecificas con enlazadores selectivamente escindibles.
|
|
JP2023505256A
(ja)
|
2019-12-05 |
2023-02-08 |
ソレント・セラピューティクス・インコーポレイテッド |
腫瘍ターゲティング抗体と組み合わせた抗ｃｄ４７抗体を含む組成物および方法
|
|
AU2021214795A1
(en)
|
2020-01-31 |
2022-08-18 |
The Cleveland Clinic Foundation |
Anti-Müllerian Hormone Receptor 2 antibodies and methods of use
|
|
WO2021173612A1
(en)
|
2020-02-26 |
2021-09-02 |
Sorrento Therapeutics, Inc. |
Activatable antigen binding proteins with universal masking moieties
|
|
WO2021195089A1
(en)
|
2020-03-23 |
2021-09-30 |
Sorrento Therapeutics, Inc. |
Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
|
|
EP3889183A1
(de)
|
2020-04-01 |
2021-10-06 |
Pierre Fabre Medicament |
Proteinkomplex mit einem immunzytokin
|
|
US20230167191A1
(en)
|
2020-04-24 |
2023-06-01 |
Sorrento Therapeutics, Inc. |
Memory Dimeric Antigen Receptors (mDARs)
|
|
WO2021217032A2
(en)
|
2020-04-24 |
2021-10-28 |
Sorrento Therapeutics, Inc. |
Lateral flow device for detection of coronavirus infection
|
|
EP4151655A1
(de)
|
2020-05-14 |
2023-03-22 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-cd25-antikörper, antigenbindende fragmente davon und medizinische verwendungen davon
|
|
WO2021247812A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Bispecific binding constructs
|
|
WO2021253002A1
(en)
|
2020-06-12 |
2021-12-16 |
Gigagen, Inc. |
Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
|
|
EP4172207A1
(de)
|
2020-06-26 |
2023-05-03 |
Sorrento Therapeutics, Inc. |
Anti-pd1-antikörper und verwendungen davon
|
|
US20230357793A1
(en)
|
2020-06-26 |
2023-11-09 |
Sorrento Therapeutics, Inc. |
Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
|
|
TW202233660A
(zh)
|
2020-10-30 |
2022-09-01 |
美商安進公司 |
過表現胰島素樣生長因子受體突變體以調節ｉｇｆ補充
|
|
US20240019426A1
(en)
|
2020-11-04 |
2024-01-18 |
Sorrento Therapeutics, Inc. |
Lateral Flow Devices for High Sensitivity Detection of Coronavirus Infection, and Methods of Making and Using the Same
|
|
JP2023553384A
(ja)
|
2020-12-03 |
2023-12-21 |
アムジエン・インコーポレーテツド |
複数の結合ドメインを有する免疫グロブリン構築物
|
|
WO2022184082A1
(en)
|
2021-03-03 |
2022-09-09 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates comprising an anti-bcma antibody
|
|
TW202304990A
(zh)
|
2021-03-26 |
2023-02-01 |
美商健生生物科技公司 |
針對成對螺旋絲ｔａｕ之人源化抗體及其用途
|
|
WO2022261262A1
(en)
|
2021-06-09 |
2022-12-15 |
Sorrento Therapeutics, Inc. |
Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device
|
|
KR20240049265A
(ko)
|
2021-06-18 |
2024-04-16 |
테리니 바이오, 인코포레이티드 |
인간 피브린 또는 피브리노겐 γC 도메인에 결합하는 항체 및 사용 방법
|
|
TW202328442A
(zh)
|
2021-09-10 |
2023-07-16 |
美商安進公司 |
平臺宿主對ｉｇｆ—培養基之適應
|
|
EP4489790A1
(de)
|
2022-03-10 |
2025-01-15 |
Vivasor, Inc. |
Antikörper-wirkstoff-konjugate und verwendungen davon
|
|
EP4490183A1
(de)
|
2022-03-11 |
2025-01-15 |
JANSSEN Pharmaceutica NV |
Multispezifische antikörper und verwendungen davon
|
|
CA3254615A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
MULTISPECIFIC ANTIBODIES AND THEIR USES
|
|
IL315541A
(en)
|
2022-03-11 |
2024-11-01 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and their uses
|
|
WO2024121380A1
(en)
|
2022-12-08 |
2024-06-13 |
Pierre Fabre Medicament |
Vaccinal composition and adjuvant
|
|
EP4687997A2
(de)
|
2023-04-05 |
2026-02-11 |
Sorrento Therapeutics, Inc. |
Antikörper-wirkstoff-konjugate und verwendungen davon
|
|
WO2024211234A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
EP4687995A1
(de)
|
2023-04-05 |
2026-02-11 |
Sorrento Therapeutics, Inc. |
Antikörper-wirkstoff-konjugate und verwendungen davon
|
|
AU2024294028A1
(en)
|
2023-07-11 |
2026-01-22 |
Amgen Inc. |
Alternating recirculating tangential flow (artf) filtration for cell culture media perfusion and bioreactor harvesting
|
|
CN121443633A
(zh)
|
2023-07-21 |
2026-01-30 |
美国安进公司 |
掺入驱动可选择标记表达的启动子组合的载体
|
|
TW202515895A
(zh)
|
2023-08-15 |
2025-04-16 |
美商吉加根公司 |
靶向ｂ型肝炎病毒（ｈｂｖ）之重組多株蛋白及其使用方法
|
|
WO2025085682A1
(en)
|
2023-10-18 |
2025-04-24 |
Amgen Inc. |
Evaluation of mrna transcript levels using ddpcr for early pool and single-cell clone assessment in cell line development
|
|
WO2025137523A2
(en)
|
2023-12-20 |
2025-06-26 |
Apogee Therapeutics, Inc. |
Pharmaceutical formulations of antibodies that bind interleukin 13
|
|
TW202535935A
(zh)
|
2023-12-20 |
2025-09-16 |
美商艾普吉醫療股份有限公司 |
結合介白素13之抗體之醫藥組合物
|
|
WO2025155774A2
(en)
|
2024-01-19 |
2025-07-24 |
Amgen Inc. |
Vector engineering strategies to enhance volumetric productivity and decrease impurity formation across a diverse set of modalities
|
|
WO2025155776A1
(en)
|
2024-01-19 |
2025-07-24 |
Amgen Inc. |
Expression vector systems with two copies of light chain
|
|
WO2025172924A1
(en)
|
2024-02-15 |
2025-08-21 |
Janssen Biotech, Inc. |
Anti-transferrin receptor compositions and methods thereof
|
|
WO2025184493A1
(en)
|
2024-02-29 |
2025-09-04 |
Amgen Inc. |
Dual selection expression vector systems for multi-chain biologics
|
|
WO2025216346A1
(ko)
|
2024-04-13 |
2025-10-16 |
주식회사 이뮨온시아 |
암 치료를 위한 pd-l1 저해제를 이용한 신보조요법
|
|
WO2025255353A1
(en)
|
2024-06-06 |
2025-12-11 |
Apogee Therapeutics, Inc. |
Dosage and administration of an anti-ox40l antibody
|
|
WO2026019782A2
(en)
|
2024-07-16 |
2026-01-22 |
Amgen Inc. |
Methods for reducing filter fouling in perfusion cell cultures with recirculating tangential flow filtration
|
|
WO2026024904A1
(en)
|
2024-07-24 |
2026-01-29 |
Gigagen, Inc. |
Custom recombinant polyclonal proteins and methods of use thereof
|